Schroder Investment Management Group’s Axsome Therapeutics AXSM Stock Holding History

Schroder Investment Management Group’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,830	Closed	-$3.82M	–	1179
2026 Q1	$3.82M	Buy	+23,830	New	+$4.12M	﹤0.01%	823
2025 Q3	–	Sell	-37,481	Closed	-$3.91M	–	1188
2025 Q2	$3.91M	Buy	37,481 +13,339	+55%	+$1.41M	﹤0.01%	816
2025 Q1	$2.86M	Hold	24,142	–	–	﹤0.01%	856
2024 Q4	$2.05M	Sell	24,142 -34,158	-59%	-$3.14M	﹤0.01%	916
2024 Q3	$5.23M	Hold	58,300	–	–	0.01%	778
2024 Q2	$4.69M	Hold	58,300	–	–	0.01%	797
2024 Q1	$4.65M	Hold	58,300	–	–	0.01%	795
2023 Q4	$4.64M	Buy	+58,300	New	+$3.9M	0.01%	780
2019 Q3	–	Sell	-5,896	Closed	-$152K	–	1279
2019 Q2	$152K	Buy	+5,896	New	+$118K	﹤0.01%	1156

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Schroder Investment Management Group's AXSM Position: Q2 2026 in Review

Schroder Investment Management Group sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 23,830 shares — an estimated $3.82M sold.

Schroder Investment Management Group first reported a position in AXSM in Q2 2019 and held it in 9 quarters. The position peaked at $5.23M in Q3 2024. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Schroder Investment Management Group reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
Schroder Investment Management Group sold 23,830 Axsome Therapeutics shares in Q2 2026, an estimated $3.82M.
Schroder Investment Management Group first reported a position in Axsome Therapeutics in Q2 2019 and held it in 9 quarters.
Schroder Investment Management Group's Axsome Therapeutics position peaked at $5.23M in Q3 2024.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.